Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Pedersen-Bjergaard

Showing results (81-90 of 100) with videos related to

Pageof 10
Sort By:
Scandinavian Journal of Haematology|October 1, 1985
Predictive value of bone marrow cultures in 48 patients with acute myeloblastic leukaemia or myelodysplasia both secondary to treatment of other malignant diseasesB T Mortensen, J Pedersen-Bjergaard, N Tinggaard Pedersen, et al.
Cancer|August 1, 1984
Acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome secondary to treatment of other malignant diseases. II. Bone marrow cytology, cytogenetics, results of HLA typing, response to antileukemic chemotherapy, and survival in a total series of 55 patientsJ Pedersen-Bjergaard, P Philip, N T Pedersen, et al.
Cancer Treatment Reports|October 1, 1980
VP-16-213 in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone in the treatment of non-Hodgkin's lymphomasM M Hansen, C D Bloomfield, J Jørgensen, et al.
Cancer|July 1, 1983
A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I-II non-Hodgkin's lymphomasN I Nissen, J Ersbøll, H S Hansen, et al.
Cancer Treatment Reports|October 1, 1984
Aclarubicin in the treatment of acute nonlymphocytic leukemia refractory to treatment with daunorubicin and cytarabine: a phase II trialJ Pedersen-Bjergaard, H Brincker, J Ellegaard, et al.
Lancet (London, England)|July 11, 1987
Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapyJ Pedersen-Bjergaard, L Specht, S O Larsen, et al.
Blood|July 1, 1982
Varying involvement of peripheral granulocytes in the clonal abnormality - 7 in bone marrow cells in preleukemia secondary to treatment of other malignant tumors: cytogenetic results compared with results of flow cytometric DNA analysis and neutrophil chemotaxisJ Pedersen-Bjergaard, L Vindeløv, P Philip, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 26, 1994
Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3;21)(q26;q22) translocationsG Nucifora, C R Begy, H Kobayashi, et al.
Annals of Internal Medicine|August 1, 1985
Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agentsJ Pedersen-Bjergaard, J Ersbøll, H M Sørensen, et al.
Cancer|January 1, 1980
Acute non-lymphocytic leukemia in patients with ovarian carcinoma following long-term treatment with Treosulfan (= dihydroxybusulfan)J Pedersen-Bjergaard, N I Nissen, H M Sørensen, et al.
Pageof 10

Showing results (81-90 of 100) with videos related to

Sort By:
Pageof 10
Scandinavian Journal of Haematology|October 1, 1985
Predictive value of bone marrow cultures in 48 patients with acute myeloblastic leukaemia or myelodysplasia both secondary to treatment of other malignant diseasesB T Mortensen, J Pedersen-Bjergaard, N Tinggaard Pedersen, et al.
Cancer|August 1, 1984
Acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome secondary to treatment of other malignant diseases. II. Bone marrow cytology, cytogenetics, results of HLA typing, response to antileukemic chemotherapy, and survival in a total series of 55 patientsJ Pedersen-Bjergaard, P Philip, N T Pedersen, et al.
Cancer Treatment Reports|October 1, 1980
VP-16-213 in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone in the treatment of non-Hodgkin's lymphomasM M Hansen, C D Bloomfield, J Jørgensen, et al.
Cancer|July 1, 1983
A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I-II non-Hodgkin's lymphomasN I Nissen, J Ersbøll, H S Hansen, et al.
Cancer Treatment Reports|October 1, 1984
Aclarubicin in the treatment of acute nonlymphocytic leukemia refractory to treatment with daunorubicin and cytarabine: a phase II trialJ Pedersen-Bjergaard, H Brincker, J Ellegaard, et al.
Lancet (London, England)|July 11, 1987
Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapyJ Pedersen-Bjergaard, L Specht, S O Larsen, et al.
Blood|July 1, 1982
Varying involvement of peripheral granulocytes in the clonal abnormality - 7 in bone marrow cells in preleukemia secondary to treatment of other malignant tumors: cytogenetic results compared with results of flow cytometric DNA analysis and neutrophil chemotaxisJ Pedersen-Bjergaard, L Vindeløv, P Philip, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 26, 1994
Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3;21)(q26;q22) translocationsG Nucifora, C R Begy, H Kobayashi, et al.
Annals of Internal Medicine|August 1, 1985
Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agentsJ Pedersen-Bjergaard, J Ersbøll, H M Sørensen, et al.
Cancer|January 1, 1980
Acute non-lymphocytic leukemia in patients with ovarian carcinoma following long-term treatment with Treosulfan (= dihydroxybusulfan)J Pedersen-Bjergaard, N I Nissen, H M Sørensen, et al.
Pageof 10